EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mucorales PCR Testing in Respiratory and Biopsy Samples From Immunocompromised Patients With Invasive Pulmonary Aspergillosis and Other Mold Infections: Results From a Multicenter ECMM Study

Sarah Sedik iD, Robina Aerts iD, Katrien Lagrou iD, Yuri Vanbiervliet iD, Johan A Maertens, P Lewis White, Raquel B Posso, Silke Schelenz, Alireza Abdolrasouli, Jochem B Buil iD, Karl Dichtl, Harald H Kessler und 2 weitere

Open Forum Infectious Diseases · 26.12.2025 · 13 (1)

DOI: 10.1093/ofid/ofaf801 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 30.12.2025. Verfasst von Sarah Sedik und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Infectious Diseases, Medical University of Graz, Translational Mycology Research Center, Excellence Cent…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer, Sofie Vanmechelen and Kurt Beuselinck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mucormycosis is a severe fungal infection that is challenging to diagnose as traditional methods lack sensitivity and serological testing is unavailable. This study aimed to evaluate the MucorGenius® PCR assay on respiratory and biopsy samples from high-risk patients with probable/proven invasive pulmonary aspergillosis (IPA), mucormycosis, or possible invasive mold infections (IMIs).

Methods

This multicenter cohort study was conducted across 4 sites in Austria, Belgium and the UK. A total of 132 respiratory and biopsy samples from 114 patients with IMI diagnosed in clinical routine (10 proven IPA, 13 proven mucormycosis, 62 probable IPA, 5 probable mucormycosis, and 35 possible IMI according to EORTC/MSGERC 2020 and FUNDICU criteria; 11 IPA/mucormycosis coinfections) were analyzed using the MucorGenius® PCR assay in ISO-certified laboratories. Results were compared with standard fungal diagnostics.

Results

Mucorales DNA was detected in 37/132 samples (28%) including 29 BAL fluids, 1 bronchial aspirate, 1 endotracheal aspirate, and 6 biopsies from 37 patients. Sensitivity was 94.4% (17/18) for detecting probable/proven mucormycosis (including 11 cases routinely diagnosed with IPA/mucormycosis coinfection). Among 72 patients with probable/proven IPA, 21 (29.2%) tested positive for Mucorales DNA, including 11 missed by routine diagnostics. Mucorales DNA was also detected in 9/35 (25.7%) of patients with possible IMI.

Conclusions

MucorGenius® PCR showed high sensitivity for detecting Mucorales and may support improved diagnosis of probable mucormycosis when included as a mycological criterion. It appears particularly valuable for identifying Aspergillus-Mucorales coinfections and detecting mucormycosis in patients with host factors, clinical or radiological evidence of IMI when routine diagnostics are negative.

Schlagwörter

Stichwörter der Autor:innen

AspergillusPCRbronchoalveolar lavageinvasive mold infectionmucorales

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Infectious Diseases, Medical University of Graz, Translational Mycology Research Center, Excellence Centre for Medical Mycology (ECMM), Graz, Austria.
  • Department of Microbiology, Immunology and Transplantation KU Leuven, Leuven, Belgium.
  • Department of Laboratory Medicine, National Reference Center for Mycosis and Excellence Centre for Medical Mycology (ECMM) UZ Leuven, Leuven, Belgium.
  • Public Health Wales Mycology Reference Laboratory and Cardiff University Centre for Trials Research, University Hospital of Wales, Cardiff, UK.
  • Infection Sciences, King's College Hospital, London, UK.
  • Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.

ORCID-Profile: Sarah Sedik, Robina Aerts, Katrien Lagrou, Yuri Vanbiervliet, Jochem B Buil, Juergen Prattes, Martin Hoenigl

Förderung

  • Pfizer
  • Sofie Vanmechelen and Kurt Beuselinck

Zitieren

APA

Sedik, S., Aerts, R., Lagrou, K., Vanbiervliet, Y., Maertens, J. A., White, P. L., Posso, R. B., Schelenz, S., Abdolrasouli, A., Buil, J. B., Dichtl, K., Kessler, H. H., Prattes, J., & Hoenigl, M. (2025). Mucorales PCR Testing in Respiratory and Biopsy Samples From Immunocompromised Patients With Invasive Pulmonary Aspergillosis and Other Mold Infections: Results From a Multicenter ECMM Study. Open Forum Infectious Diseases, 13(1). https://doi.org/10.1093/ofid/ofaf801

Vancouver

Sedik S, Aerts R, Lagrou K, Vanbiervliet Y, Maertens JA, White PL, et al. Mucorales PCR Testing in Respiratory and Biopsy Samples From Immunocompromised Patients With Invasive Pulmonary Aspergillosis and Other Mold Infections: Results From a Multicenter ECMM Study. Open Forum Infectious Diseases. 2025;13(1). doi:10.1093/ofid/ofaf801

BibTeX
@article{Sedik2025,
  author = {Sedik, Sarah and Aerts, Robina and Lagrou, Katrien and Vanbiervliet, Yuri and Maertens, Johan A and White, P Lewis and Posso, Raquel B and Schelenz, Silke and Abdolrasouli, Alireza and Buil, Jochem B and Dichtl, Karl and Kessler, Harald H and Prattes, Juergen and Hoenigl, Martin},
  title = {Mucorales PCR Testing in Respiratory and Biopsy Samples From Immunocompromised Patients With Invasive Pulmonary Aspergillosis and Other Mold Infections: Results From a Multicenter ECMM Study},
  journal = {Open Forum Infectious Diseases},
  year = {2025},
  volume = {13},
  number = {1},
  doi = {10.1093/ofid/ofaf801}
}
Kostenlos starten →